Design and synthesis of mono and bicyclic tetrapeptides thioester as potent inhibitor of histone deacetylases
Tóm tắt
Inhibitors of histone deacetylases (HDACs) are a promising class of anticancer agents that have an effect on gene regulation. The naturally occurring cyclic depsipeptide FK228 containing disulfide and Largazole possessing thioester functionalities act as pro-drugs and share the same HDAC inhibition mechanism in cell. Inspired from these facts, we have reported bicyclic tetrapeptide disulfide HDAC inhibitors resembling FK228 with potent activity and enhanced selectivity. In the present study, we report the design and synthesis of several mono and bicyclic tetrapeptide thioester HDAC inhibitors that share the inhibition mechanism similar to Largazole. Most of the compounds showed HDAC1 and HDAC4 inhibition and p21 promoting activity in nanomolar ranges. Among these the monocyclic peptides 1, 2 and bicyclic peptide, 4 are notable demanding more advanced research to be promising anticancer drug candidates.
Tài liệu tham khảo
Archer SY, Hodin RA (1999) Histone acetylation and cancer. Curr Opin Genet Dev 9:171–174. doi:10.1016/S0959-437X(99)80026-4->
Bhuiyan MPI, Kato T, Okauchi T et al (2006) Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases. Bioorg Med Chem 14:3438–3446. doi:10.1016/j.bmc.2005.12.063
Butler KV, Kozikowski AP (2008) Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharm Des 14:505–528. doi:10.2174/138161208783885353
Cress WD, Seto E (2000) Histonedeacetylases, transcriptional control and cancer. J Cell Physiol 184:1–16
Dickinson M, Prince HM (2012) Romidepsin for relapsed and refractory cutaneous T-cell lymphoma clinical medicine insights. Dermatology 5:21–28. doi:10.4137/CMD.S7252
Frey RR, Wada CK, Garland RB (2002) Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett 12:3443–3447. doi:10.1016/S0960-894X(02)00754-0
Furumai R, Matsuyama A, Kobashi M (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class 1 histone deacetylases. Cancer Res 62:4916–4921
Grozinger CM, Schreiber SL (2002) Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 9:3–16
Hassig CA, Schreiber SL (1997) Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1:300–308. doi:10.1016/S1367-5931(97)80066-X
Hoque AH, Yoshida M et al (2012) Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors of histone deacetylases. Bioorg Med Chem Lett 22:6770–6772. doi:10.1016/j.bmcl.2012.03.004
Islam NM, Nishino N et al (2010) Bicyclic peptides as potent inhibitors of histone deacetylases: optimization of alkyl loop length. Bioorg Med Chem Lett 20:997–999. doi:10.1016/j.bmcl.2009.12.054
Kouzarides T (1999) Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 9:40–48
Mahlknecht U, Ottmann OG, Hoelzer D (2000) When the band begins to play: histone acetylation caught in the crossfire of gene control. Mol Carcinog 27:268–271. doi:10.1002/(SICI)1098-2744(200004
Mann BS, Johnson JR et al (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12:1247–1252. doi:10.1634/theoncologist.12-10-1247
Michaelides MR, Dellaria JF, Gong J et al (2001) Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors. Bioorg Med Chem Lett 11:1553–1556. doi:10.1016/S0960-894X(01)00031-2
Mulder GJ, Meerman JH (1983) Sulfation and glucuronidation as competing pathways in the metabolism of hydroxamic acids: the role of N, O-sulfonation in chemical carcinogenesis of aromatic amines. Environ Health Perspect 49:27–32
Nishino N, Jose B, Okamura S et al (2003) Cyclic Tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases. Org Lett 5:5079–5082. doi:10.1021/ol036098e
Nishino N, Jose B et al (2004) Chlamydocin–hydroxamic acid analogues as histone deacetylase inhibitors. Bioorg Med Chem 12:5777–5784. doi:10.1016/j.bmc.2004.08.041
Nishino N, Shivashimpi GM et al (2008) Interaction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides. Bioorg Med Chem 16:437–445. doi:10.1016/j.bmc.2007.09.021
Shivashimpi GM, Amagai S, Kato T et al (2007) Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem 15:7830–7839. doi:10.1016/j.bmc.2007.08.041
Suzuki T, Kouketsu A, Itoh Y et al (2006) Highly potent and selective histone deacetylase 6 inhibitors designed based on small-molecular substrate. J Med Chem 49:4809–4812. doi:10.1021/jm060554y
Taori K, Paul VJ, Luesch H (2008) Structure and Activity of Largazole, a Potent Antiproliferative Agent from the Floridian Marine Cyanobacterium Symploca sp. J Am Chem Soc 130:1806–1807. doi:10.1021/ja7110064
Watanabe LA, Jose B, Kato T, Nishino N, Yoshida M (2004) Synthesis of L-a-amino-w-bromoalkanoic acid for side chain modification. Tetrahedron Lett 45(3):491–494. doi:10.1016/j.tetlet.2003.11.007
Yoshida M, Matsuayama A, Komatsu Y, Nishino N (2003) From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem 10:2351–2358. doi:10.2174/092986708784049612
Zain J, Kaminetzky D, O’Connor OA (2010) Emerging role of epigenetic therapies in cutaneous T-cell lymphomas. Expert Rev Hematol 3:187–203. doi:10.1586/ehm.10.9